-
SARS-CoV-2 N Protein Rewires GADD34 Signaling
2026-09-09
The reference study identifies an atypical stress-granule mechanism through which SARS-CoV-2 nucleocapsid protein suppresses GADD34 expression, restricts IRF3 nuclear localization, and weakens interferon production. Its findings connect viral RNA–protein condensates with a previously underappreciated GADD34-mediated branch of innate immune regulation and provide a framework for designing mechanistic RNA and host-response assays.
-
MDM1–p53 Control of CRC Chemoradiotherapy Response
2026-09-09
The reference study identifies MDM1 as a candidate biomarker and mechanistic regulator of colorectal cancer sensitivity to chemoradiotherapy. Its data connect MDM1 overexpression with reduced YBX1 occupancy at the TP53 promoter, increased p53 expression, and enhanced apoptosis, providing a framework for studying treatment resistance.
-
Mithramycin A: A G-C DNA Assay Strategy
2026-09-08
Mithramycin A is an anticancer antibiotic that turns G-C-rich DNA recognition into a rigorous probe of transcriptional control. This article develops a mechanistic assay strategy linking c-myc regulation and leukemia research with carefully bounded interpretation of the miR-24-3p/Sp1/PI3K cardiac study.
-
Separating Growth Inhibition from Cancer Cell Killing
2026-09-07
Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its central contribution is a framework for distinguishing proliferative arrest from genuine cell killing, with important consequences for time-course design, dose-response interpretation, and survivin inhibitor studies.
-
FAISL–Calpain 2–FAK Signaling in TNBC
2026-09-07
The reference study identifies FAISL as a long noncoding RNA that stabilizes focal adhesion kinase by blocking calpain 2-mediated proteolysis, thereby promoting adhesion, survival, proliferation, and metastasis in triple-negative breast cancer. Its combination of transcriptomic discovery, molecular interaction analysis, cellular assays, and nanoparticle-enabled in vivo silencing provides a framework for studying proteolytic regulation of focal adhesion signaling.
-
Gentamycin Sulfate for Resistance Assay Design
2026-09-05
Gentamycin Sulfate can serve as more than an antibiotic challenge: it can help connect ribosome-level phenotypes with plasmid transmission and carbapenemase epidemiology. This guide translates recent CREC findings into better assay decisions, interpretation, and reagent handling.
-
Recombinant Human Oncostatin M: Assay Workflows
2026-09-04
Build reproducible rh-Oncostatin M experiments for fibroblast, smooth muscle, tumor-cell, and cytokine-release models. This workflow pairs product-specific handling guidance with a cautious extension of new X-chromosome-inactivation research into cytokine-response assay design.
-
LncRNA MRF, FSHR, and BMSC Osteogenesis
2026-09-04
Ning et al. identify lncRNA MRF as a negative regulator of bone marrow mesenchymal stem cell osteogenesis, linking its activity to FSHR and the cAMP-PKA-CREB pathway. The study combines cellular perturbation, transcriptome analysis, protein validation, and a mouse bone-defect model to connect molecular regulation with bone repair.
-
V5 Epitope Tag Peptide: Practical Workflows
2026-09-04
Build more reliable recombinant-protein assays with a V5 control that supports antibody validation, Western blotting, immunoprecipitation, and microscopy-oriented workflows. This guide connects routine peptide competition tests with the fast-dissociation antibody-screening strategy reported in single-molecule research.
-
Metal-Chelating l-Phe Nanostructures Boost ICB
2026-09-03
This Nature Nanotechnology study introduces metal-ion-chelating l-phenylalanine nanostructures that reshape dendritic-cell electrophysiology and counter immune suppression in breast and colorectal tumour models. Combined with short-term starvation, the nanostructures enhanced dendritic-cell maturation and tumour-specific cytotoxic T-cell activity, thereby sensitizing tumours to immune checkpoint blockade.
-
Multiple Myeloma Cell Lines: Mutations and Drug Resistance
2026-09-02
This 2019 Theranostics study used whole-exome sequencing to define the mutational landscape of 30 human multiple myeloma cell lines and connect genomic alterations with oncogenic pathways and drug response. Its main contribution is a practical framework for selecting better-characterized cell-line models while identifying candidate drivers of tumor progression and therapeutic resistance.
-
Regorafenib, RRM2, and Melanoma Progression
2026-09-02
This 2024 iScience study identifies RRM2 reduction and ERK/E2F3 signaling as key components of regorafenib activity in melanoma models. Its combination of transcriptomics, functional assays, rescue experiments, and in vivo validation provides a mechanism-focused framework for cancer biology research beyond conventional antiangiogenic interpretation.
-
How Clinically Safe Drugs Redirect CRISPR DNA Repair
2026-09-01
Macak, Kanis, and Riesenberg screened more than 7,000 FDA-approved drug conditions in human induced pluripotent stem cells to identify compounds that shift CRISPR-induced double-strand break repair toward NHEJ, MMEJ, or HDR. The study also links ESR2 and AOX1 to DNA repair regulation and highlights drug-based pathway control as a potential tool for genome engineering and synthetic lethality.
-
MDM1, p53, and Chemoradiotherapy Sensitivity in CRC
2026-09-01
The reference study identifies MDM1 as a functional determinant of colorectal cancer chemoradiotherapy response and connects its activity to YBX1-dependent control of TP53 expression and apoptosis. Its combined genetic, transcriptomic, cellular, and xenograft evidence supports MDM1 as a candidate predictive biomarker and provides a rationale for apoptosis-focused strategies in MDM1-low tumors.
-
JAK Inhibitors Block RA Synovial Fluid Neuron Activation
2026-08-31
This preprint identifies a direct effect of JAK inhibition on human sensory neurons exposed to rheumatoid arthritis synovial fluid. Its combination of patient-derived fluid, transcriptomic analysis, phospho-STAT3 immunoblotting, neuronal electrophysiology, and pain-related gene assays provides a mechanistic framework for understanding the analgesic effects of JAK inhibitors.